Last month, Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) commenced trading on the Canadian Stock Exchange (CSE) and is an opportunity that we have been closely following.
We consider Havn Life to be an attractive play on the burgeoning psychedelic therapy market and believe that the opportunity is flying under the radar after the listing. The biotech company has been focused on using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi to treat mental disorders and we are bullish on the potential that is associated with this opportunity
When it comes to any emerging industry, the management team is the most important aspect of any company. In regard to the psychedelic therapy market, the strength of the management team is of the utmost importance and we find this to be a key aspect of the Havn Life story. During the last month, the company has made some key additions to the team and we want to provide an update on this.
Announces Significant Additions to the Team
Last week, Havn Life announced that Vic Neufeld has been appointed as the Chairman of the Board of Directors and we consider the addition to be strategic. He adds a wealth of knowledge and experience in the Natural Health Food industry, having served as the Chief Executive Officer of Jamieson Laboratories, Canada’s largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements, herbs and botanical medicines.
While working at Jamieson for more than 20 years, Neufeld played an important role with how sales went from $20 million per year to more than approx. $250 million per year and expanded its distribution network to 40+ countries/ Neufeld was part of the team responsible for building Jamieson to a globally recognized brand name and we are favorable on the success that he has also had in the cannabis sector.
Many psychedelics therapy companies have tried to get Neufeld involved with the business and we believe that him choosing Havn Life speaks volumes to the quality of the deal. According to Neufeld, he selected Havn Life due to how the business is positioned with the right operational team, vision and business model to establish itself as a leader in this psychedelics sector.
As executives with track records that are as proven as Neufeld enter the psychedelics sector, we believe that the industry becomes more credible. This is a trend that is just getting started and we expect to see additional high-profile executives from the biotech and cannabis industries enter the psychedelic sector.
Another reason that helps explain why Neufeld selected Havn Life is related to the type of work its conducting to create a leading nutraceutical wellness brand through the Havn Retail division as well as the type of cutting-edge research and development that is being conducted by the Havn Labs division.
Concurrent with the addition of Vic Neufeld, Havn Life also announced the appointment of Rick Brar as the Vice Chairman of the Board. He is an experienced business leader in the cannabis, nutraceutical, beverage, consumer packaged goods (CPG), agriculture, land development and construction sectors. We are favorable the type of expertise that he adds to the team and will monitor the impact he has on the business.
Brar has international expertise in emerging market sectors and we are favorable on how this background will help Havn Life. He is experienced in sales and marketing, with a track record of success in corporate sales growth, new market penetration, new product development, and long-range planning.
We expect Brar to play an important role in the success of Havn Life. He is also experienced in team building, strategic planning, new market development and the implementation of tactical sales and marketing initiatives. Currently. He is the Chief Executive Officer and Chairman of Brains Bioceutical, a global manufacturer and distributor of cannabinoid active pharmaceutical ingredients (API) and we are favorable on his involvement.
Forms Strategic Partnership to Advance the Industry
A few days before these two appointments were announced, Havn Life reported to have joined the Drug Science Medical Psychedelics Working Group consortium. The working group was launched by a leading independent scientific committee that is based in the United Kingdom. The working group provides evidence-based research and creates a foundation for sensible and effective drug laws by reviewing and investigating scientific evidence that is related to psychoactive drugs.
The development falls in-line with Havn Life’s commitment to advancing research in psychedelics, as well as collaborating with organizations and academic institutions around the world to tap into world-class, quality research. The companies have come together to support the development of sensible drug policy reform and we are favorable on how the relationship further differentiates the opportunity from its peers
One of the reasons we are excited about the relationship is due to the amount and the quality of human capital that is involved. The team is comprised of drug science experts, industry partners, patient representatives, and policymakers. The group’s mission is to break the barriers of 50 years of medical censorship by creating an approach to psychedelic research and clinical treatment.
Some of the key players on the team include:
- David Nutt – serves as Chair of the Scientific Committee and is also a professor of Neuropsychopharmacology at Imperial College London.
- Colonel Rakesh Jetly – served in the Canadian military and spent time as a senior psychiatrist and a mental health clinical advisor to the CF Surgeon General ]
- Joanna Neil – a professor of Psychopharmacology at the University of Manchester that has been conducting research on the development of preclinical models of psychiatric disorders in psychopharmacology for almost 30 years
An Opportunity to be Aware of
After Havn Life commenced trading on the CSE, the market responded favorably to the listing and this is a trend that has not been seen at most psychedelic focused companies. We believe the market finds the strength of the management team to be an important aspect of the story and we are favorable on how Havn Life has made this a priority for the business.
Currently, Havn Life is in the final stages of product development and expects to have products available in nutraceutical retailers in the near future. We are bullish on the growth prospects that are associated with the strategy that the company put in-place and will monitor how the story advances from here.
Over the next year, we expect to receive several updates on Havn’s multi-faceted growth strategy and are favorable on the amount of potential upside that is associated with the opportunity. We believe Havn Life has been flying under the radar and this is a trend that we do not expect to last.
If you are interested in learning more about Havn Life, please send an email to email@example.com with the subject “Havn Life” to be added to our distribution list.
Pursuant to an agreement between StoneBridge Partners LLC and HAVN Life Sciences we have been hired for a period of 180 days beginning June 1, 2020 and ending December 1, 2020 to publicly disseminate information about (HAVN) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (HAVN) for or were paid “0” shares of restricted common shares. We own zero shares of (HAVN), which we purchased in the open market. We plan to sell the “ZERO” shares of (HAVN) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (HAVN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.